BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

A2 is engineering T cell therapies that selectively attack solid tumor cells by exploiting the loss of genetic material in tumors.  The T cell module (Tmod) consists of an engineered T cell with an “activator”...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine. Shares of TCR...
BioCentury | Jul 21, 2020

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

For the second time in as many months, Gilead has made a large investment in a biotech in the cancer immunosuppression area, paying $300 million up front to acquire nearly half of privately-held Tizona with...
BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

Making machine learning an effective tool in the fight against COVID-19 requires broad access to data, scrupulous checks for bias, and strategies to balance speed and accuracy, according to researchers with AI-based diagnostics and literature-mining...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
Items per page:
1 - 10 of 679